[Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications]

Area of Science:

• Endocrinology
• Genetics
• Oncology

Background:

• Multiple endocrine neoplasia type 2 (MEN 2) is a rare autosomal dominant disorder.
• MEN 2 predisposes individuals to various endocrine gland tumors.
• Early diagnosis and management are crucial for patient outcomes.

Purpose of the Study:

• To review the clinical features and diagnostic approaches for MEN 2.
• To highlight advancements in biochemical screening and genetic analysis for MEN 2.
• To discuss the clinical implications of molecular biology in MEN 2 management.

Main Methods:

• Review of clinical features and diagnostic criteria for MEN 2.
• Analysis of current biochemical screening protocols.
• Evaluation of genetic testing methodologies for MEN 2 risk assessment.
• Discussion of molecular biology's impact on clinical management.

Main Results:

• MEN 2 diagnosis relies on characteristic clinical features and family history.
• Biochemical screening aids in detecting hyperparathyroidism and pheochromocytoma.
• Genetic analysis of RET proto-oncogene mutations is definitive for diagnosis and risk stratification.
• Molecular diagnostics enable personalized screening and prophylactic strategies.

Conclusions:

• Integrated diagnostic approaches combining clinical, biochemical, and genetic data are essential for MEN 2.
• Advances in molecular biology have significantly improved the early detection and management of MEN 2.
• Genetic counseling and timely interventions based on molecular findings can reduce morbidity and mortality.